Answers to Frequently Asked Questions About Humira

Humira (adalimumab) is a human monoclonal antibody. It works by blocking tumor necrosis factor alpha (TNF-alpha), a cytokine that plays a role in the inflammatory process. People with inflammatory bowel disease (IBD) have an abnormal amount of TNF-alpha, and it is thought that this plays a role in the disease process. Humira stops TNF-alpha from being used by the body.

How Humira Is Taken

Humira comes in the form of an injection and should be stored in a refrigerator. The injection is given under the skin (subcutaneously) either at home or in a doctor's office.

Humira is given once every other week or sometimes every week. The dosage is normally 40 milligrams (mg).

Humira should not be injected into the same location on the body two times in a row. Patients should rotate where they give the injection—normally the abdomen or the front of either thigh. The prescribing doctor will provide any special instructions and describe how to administer the injection at home, if necessary.

If you have questions on how to give the injection, you can call 1-800-4HUMIRA (448-6472).

Uses

Humira may be prescribed for Crohn's disease or ulcerative colitis, the two main forms of IBD. Humira is approved for use in adults and in children over the age of 6.

Humira may reduce common IBD symptoms (pain, fatigue and diarrhea) or may induce remission. In one clinical trial of patients with Crohn's disease, 40% to 47% of patients given Humira were in remission after 26 weeks of treatment. After 56 weeks, about 40% of the patients were still in remission.

Crohn's Disease

According to 2018 guidelines for Crohn's disease, anti-TNF therapy—Humira, Remicade (infliximab), or Cimzia (certolizumab pegol—is most often used for moderate or severe disease that is resistant to corticosteroids and/or immunomodulators (such as thiopurines or methotrexate).

Humira (or another anti-TNF therapy) may be used to treat severely active/fulminant disease. Humira (or Cimzia) should also be considered in treating perianal fistulas associated with Crohn's disease.

Humira or another anti-TNF agent should also be used to maintain remission (maintenance treatment) in those who achieve remission while using an anti-TNF medication. When used for maintenance, adding an immunomodulator treatment to Humira therapy should be considered.

Ulcerative Colitis

For people with moderate to severe ulcerative colitis, doctors may prescribe a biologic medication as a first-line therapy, according to the latest practice guidelines. These therapies are more likely to induce remission, and hence, reduce complications.

Biologic therapies (and small molecules) include Humira, as well as Remicade (infliximab), Simponi (golimumab), Entyvio (vedolizumab), Stelara (ustekinumab), and Xeljanz (tofacitinib).

Among people who have not yet been treated with a biologic medication, the preferred drugs are Remicade, Humira, or Entyvio. Humira may be preferred due to the ease of administration. Both Remicade and Humira have equal efficacy.

For people who achieve remission on a biologic medication, the continued use of a biologic is recommended to maintain the remission. Ideally, a biologic is combined with an immunomodulator medication for maximal control of the disease.

Warnings and Precautions About Humira

Tell your doctor if you are scheduled for any kind of surgery or have had a recent vaccination. Also let your doctor know if you have or ever had any of the following conditions:

Side Effects

The most common side effects of Humira are pain, irritation, swelling, or itching at the site of the injection. Other common side effects include headache, rash, and nausea. There is a risk of developing a serious infection when taking Humira, although it is unlikely.

Tell your doctor if you develop any signs or symptoms of an infection or if any other side effects are bothersome or don't go away.

Interactions

It is not recommended that Humira be taken with other TNF-blocking agents, such as Kineret (anakinra), live vaccines, or methotrexate.

Tell your doctor if you are taking any drugs that suppress the immune system, such as cyclosporine.

Humira should not be taken with alcohol, as doing so can cause complications. There are no known food interactions.

Safety During Pregnancy

The U.S. Food and Drug Administration (FDA) has classified Humira as a Type B drug. Studies on animals show no evidence of harm to the fetus; however, there are no adequate, well-controlled studies in pregnant women.

Humira should only be used in pregnant women when clearly needed. Notify the prescribing doctor if you become pregnant while taking Humira.

One small study showed that Humira does cross the placenta and enter the bloodstream of a fetus during the last trimester of pregnancy. Humira could be found in the infant's bloodstream up to three months after birth. It is recommended that babies born to mothers taking Humira be checked closely for infection for the first six months of life and that they not receive any live-virus vaccinations during that time period.

It is not known if Humira passes into breast milk; however, similar substances have been shown to pass into breast milk. Breastfeeding while taking Humira is not recommended.

What to Do About a Missed Dose

If you miss a dose, take it as soon as you remember. Then take your next dose at the regularly scheduled time. Don't double-up or take more than one dose at a time.

Was this page helpful?
Article Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Perše M, Unkovič A. The Role of TNF in the Pathogenesis of Inflammatory Bowel DiseaseGastroenteritis [Working Title]. 2019. doi:10.5772/intechopen.84375.

  2. Kamat N, Kedia S, Ghoshal UC, et al. Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter studyIndian Journal of Gastroenterology. 2019;38(1):44-54. doi:10.1007/s12664-018-0922-1

  3. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn's disease in adultsAm J Gastroenterol. 2018;113(4):481-517. doi:10.1038/ajg.2018.27

  4. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020;158(5):1450-1461. doi:10.1053/j.gastro.2020.01.006

  5. Shiber AJ, Chowdhury BA, Swann Pundefined. HUMIRA (adalimumab) - FDA. fda.gov.

  6. Scheinfeld N. Adalimumab: a review of side effectsExpert Opinion on Drug Safety. 2005;4(4):637-641. doi:10.1517/14740338.4.4.637

  7. Puchner A, Gröchenig HP, Sautner J, et al. Immunosuppressives and biologics during pregnancy and lactation : A consensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and RehabilitationWien Klin Wochenschr. 2019;131(1-2):29–44. doi:10.1007/s00508-019-1448-y

Additional Reading
Related Articles